Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Ensemble Therapeutics, a biotechnology company, and Genentech, a member of the Roche Group, have entered into a collaboration to discover macrocyclic drug candidates against Genentech's biological targets.
Subscribe to our email newsletter
The drug discovery collaboration will leverage Ensemble’s drug discovery platform, including its Ensemblin collection of over 5m macrocycles.
Ensemble CEO Michael Taylor said, "This collaboration further validates the wide-ranging potential of our Ensemblin drug discovery platforms while providing Ensemble with additional resources to advance our own internal pipeline."
As per the terms of the agreement, Ensemble will obtain an undisclosed upfront payment, milestone payments with the achievement of certain development milestones and royalties on future sales of products that arise from the collaboration.
Genentech will have the right to develop and commercialize lead molecules arising from the partnership.
Genentech partnering vice president James Sabry said Ensemble’s approach to develop macrocyclic small molecules to address drug discovery targets that have proven difficult to modulate with traditional approaches could result in new medicines.